• Home
  • Search Results

Search Results

2779 studies match your search
Open

Chronic Lymphocytic Leukemia Study

Do you have chronic lymphocytic leukemia and have not received a previous treatment for your cancer? You may be able to take part in a new research study comparing treatments for Chronic Lymphocytic Leukemia.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Leukemia)
Not currently enrolling

Stage 3a AL Amyloidosis Study

This clinical trial will study a drug known as CAEL-101. CAEL-101 is a monoclonal antibody. The purpose of the study is to learn if CAEL-101 helps people with AL amyloidosis that has affected their hearts to live longer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Multiple Myeloma)
Not currently enrolling

Prostate Cancer Study

This is a research study to learn if a new experimental drug when given with standard of care is safe and effective as a treatment for men with metastatic hormone-sensitive prostate cancer (mHSPC). The drugs that are part of this study are Docetaxel and Radium-223.

Age & Gender
  • 18 years ~ 99 years
  • Male
Study Interest
  • Cancer (Prostate)
  • Urinary and Bladder
  • Men's Health
Open

Study of a Combination of Chemotherapy and Immunotherapy for Bladder Cancer

Have you been diagnosed with bladder cancer? You may be able to take part in a research study looking at a combination of chemotherapy drugs given with immunotherapy for patients with muscle invasive bladder cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder)
  • Urinary and Bladder
Open

Menopause and Heart Health Study

Are you experiencing symptoms of menopause? Have you noticed a change in your mood during your menopausal transition? If you have missed at least two periods, you may be able to take part in a research study. In this study, we want to learn how mood and stress may affect risk for heart disease in women during menopause.

Age & Gender
  • 44 years ~ 55 years
  • Female
Study Interest
  • Aging
  • Brain, Head, Nervous System
  • Glands and Hormones
  • and 6 more

Stage 3b AL Amyloidosis Study

The purpose of the study is to learn if the study drug (CAEL-101) helps people with AL amyloidosis that has affected their hearts to live longer. CAEL-101 is a monoclonal antibody, which is made to bind to specific things in your body like the proteins that cause AL amyloidosis

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Multiple Myeloma)
Open

Biomarker for cervical cancer screening study

If so, you may be able to take part in a research study that aims to identify non-invasive biomarkers for cervical cancer screening and monitoring following treatment of abnormal areas on the cervix caused by HPV.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Cervical)
  • Immune System/Infections
  • Sexual and/or Reproductive Health
  • Women's Health

Transplant-Ineligible Multiple Myeloma Study

In this study, we want to learn more about the impact on progression-free survival (PFS) for patients with multiple myeloma when taking a combination of four drugs. The four drugs in this study are lenalidomide, ixazomib, dexamethasone, and daratumumab.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Multiple Myeloma)
  • Transplant
Open

A Study of Investigational Medication for Relapsed or Refractory Multiple Myeloma

Do you have relapsed or refractory multiple myeloma? Have you received at least one type of treatment? If so, you may be able to take part in a research study looking at the the safety of giving an investigational medication to patients with multiple myeloma.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Multiple Myeloma)
Open

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Have you been diagnosed with CD30 negative peripheral T-cell lymphoma? If so, you may be able to take part in a research study that will look at the safety of adding the new study drug duvelisib, or the new study drug CC-486, to the standard chemotherapy treatment for your disease. Please contact us with questions about eligibility, or if you wish to know more.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lymphoma)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research